<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Special Considerations, Incentives, and Programs To Support the Approval of New Animal Drugs for Minor Uses and for Minor Species; Draft Guidance for Industry; Availability; Extension of Comment Period</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <style>
        body { font-family: Arial, sans-serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { color: #333; }
        .metadata { color: #666; font-size: 0.9em; }
        .summary { margin-top: 20px; line-height: 1.5; }
        .source { margin-top: 20px; }
    </style>
</head>
<body>
    <h1>Special Considerations, Incentives, and Programs To Support the Approval of New Animal Drugs for Minor Uses and for Minor Species; Draft Guidance for Industry; Availability; Extension of Comment Period</h1>
    <div class="metadata">Published: 2026-02-05 10:30:40</div>
    <div class="summary">The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice of availability that appeared in the Federal Register of July 15, 2020. In that notice, FDA requested comments on draft guidance for industry (GFI) #61 entitled "Special Considerations, Incentives, and Programs to Support the Approval of New Animal Drugs for Minor Uses and for Minor Species." FDA is taking this action in response to a request for an extension to allow interested persons additional time to submit comments.</div>
    <div class="source">Source: <a href="https://www.federalregister.gov/documents/2020/11/10/2020-24970/special-considerations-incentives-and-programs-to-support-the-approval-of-new-animal-drugs-for-minor" target="_blank" rel="noopener noreferrer">https://www.federalregister.gov/documents/2020/11/10/2020-24970/special-considerations-incentives-and-programs-to-support-the-approval-of-new-animal-drugs-for-minor</a></div>
</body>
</html>
